Palvella Therapeutics, Inc. - Common Stock (NQ: PVLA )

19.22 +0.22 (+1.16%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	32,161
Open	18.97
Bid (Size)	19.00 (1)
Ask (Size)	19.22 (8)
Prev. Close	19.00
Today's Range	18.05 - 19.64
52wk Range	11.17 - 21.71
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

February 20, 2025

Via Benzinga

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

February 10, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	+60.17%	+60.17%
1 Month	+46.16%	+46.16%
3 Month	+49.81%	+49.81%
6 Month	+49.81%	+49.81%
1 Year	+49.81%	+49.81%

More News

This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday

February 05, 2025

Via Benzinga

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

January 10, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations

January 08, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.